Biomarkers Consortium Programs
The identification of new biomarkers is an increasingly essential element of predictive, preventive and personalized medicine. To meet this need, The Biomarkers Consortium projects serve to develop promising biomarkers in order to help accelerate the delivery of successful new technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.
Pre-competitive Analytical Validation of SV2A PET as a Biomarker of Synaptic Density (SV2A PET Project)
Supporting the development of clinically effective therapies for Alzheimer’s disease by validating a new imaging tool to measure brain condition